F. Hoffmann-La Roche AG


Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry eight years in a row by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2016 employed more than 94,000 people worldwide. In 2016, Roche invested CHF 9.9 billion in R&D and posted sales of CHF 50.6 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

Roche retains sole responsibility for content © 2017 F. Hoffmann-La Roche Ltd. All trademarks used or mentioned in this release are protected by law.

1 April 2016 - 31 March 2017

Region: Global
Subject/journal group: All

The table to the right includes counts of all research outputs for F. Hoffmann-La Roche AG published between 1 April 2016 - 31 March 2017 which are tracked by the Nature Index.

Hover over the donut graph to view the WFC output for each subject. Below, the same research outputs are grouped by subject. Click on the subject to drill-down into a list of articles organized by journal, and then by title.

Note: Articles may be assigned to more than one subject area.

82 35.39 35.39

Outputs by subject (WFC)

Subject AC FC WFC
Chemistry 27 12.40 12.40
Life Sciences 59 24.77 24.77

Highlight of the month: F. Hoffmann-La Roche AG

Odd blood cells implicated in fibrosis

 © JUAN GARTNER/Science Photo Library/Getty

© JUAN GARTNER/Science Photo Library/Getty

A newly discovered subset of white blood cells seem to be a lynchpin in the development of the scarring disease fibrosis, researchers have found.

Fibrosis is the thickening of scar tissue during the body’s reparative process and can have serious consequences on organs such as the liver and lungs. Although researchers know that activation of the immune system is involved in the disease, there are few effective therapies.

Studying the disease in mice, scientists from the Chugai Pharmaceutical Co., Ltd and elsewhere identified an unusual subset of white blood cells that they have called SatM (segregated nucleus atypical monocytes) as being critical for fibrosis to occur.

Mice without this cell type were significantly more resistant to fibrosis, the researchers found. Introducing SatM cells into these mice increased their susceptibility to the disease.

The researchers note these results suggest it may now be possible to develop novel, more specific therapeutic targets for fibrosis with fewer side-effects.

Supported content

  1. Nature 541,96–101 (2017). doi: 10.1038/nature20611

View the article on the Nature Index

1 April 2016 - 31 March 2017

International vs. domestic collaboration by WFC

  • 8.39% Domestic
  • 91.61% International

Note: Hover over the graph to view the percentage of collaboration.

Note: Collaboration is determined by the weighted fractional count (WFC), which is listed in parentheses.

Affiliated joint institutions and consortia

Return to institution outputs